Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00821652
Recruitment Status : Completed
First Posted : January 13, 2009
Last Update Posted : January 8, 2015
Sponsor:
Collaborator:
Cancer Research Institute, New York City
Information provided by (Responsible Party):
Nina Bhardwaj, Icahn School of Medicine at Mount Sinai

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Completed
Actual Primary Completion Date : January 2010
Actual Study Completion Date : December 2014
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 March 1, 2017
April 12, 2017
2 November 28, 2017
August 10, 2018